MARCY L’ÉTOILE, France--(BUSINESS WIRE)-- Regulatory News: bioMérieux (Paris:BIM), a world leader in the field of in vitro diagnostics, today announced that BioFire Diagnostics, its subsidiary ...
This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in ...
* FILMARRA RP2 REDUCES SAMPLE-TO-RESULT TIME TO ONLY 45 MINUTES WHILE ENHANCING PATHOGEN COVERAGE AND OVERALL SENSITIVITY * FILMARRAY RP2 REDUCES SAMPLE-TO-RESULT TIME TO ONLY 45 MINUTES WHILE ...
Influenza A subtype H3, Influenza A subtype H1-2009, Influenza B virus, Parainfluenza virus, Respiratory syncytial virus and Coronavirus SARS-CoV-2. A world leader in the field of in vitro diagnostics ...
(RTTNews) - As we enter the second quarter of the year, it's time to take a look back at some of the news stories that made headlines on the regulatory front in March. BioFire Respiratory Panel 2.1 ...
On September 9, 2025, Altesa BioSciences announced a partnership with bioMérieux to use the BIOFIRE SPOTFIRE respiratory diagnostic platform as the primary point-of-care tool in its upcoming Phase 2B ...
* BIOMÉRIEUX IS CURRENTLY MAKING EVERY EFFORT TO SCALE UP SUPPLY OF BIOFIRE(®) RP2.1 PANEL AT ITS PRODUCTION FACILITIES IN SALT LAKE CITY * TEST KITS WILL BE AVAILABLE FOR COMMERCIAL DISTRIBUTION IN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback